KRAS mutations impact clinical outcome in metastatic non-small cell lung cancer

Ella A. Eklund[1,2,3], Clotilde Wiel[1,2], Henrik Fagman[4,5], Levent M. Akyürek[4,5], Sukanya

Raghavan[6], Jan Nyman[3,7], Andreas Hallqvist [3,7], Volkan I. Sayin[1,2]

[1]Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Center for Cancer

Research, University of Gothenburg, Gothenburg, Sweden; [2]Wallenberg Centre for

Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden;

[3]Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden;

[4]Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg,

Gothenburg, Sweden; [5]Department of Clinical Pathology, Sahlgrenska University

Hospital, Gothenburg, Sweden; [6]Department of Microbiology and Immunology, Institute

for Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg,

Sweden; [7]Department of Oncology, Institute of Clinical Sciences, University of

Gothenburg, Gothenburg, Sweden

Correspondence to:

V.I.S volkan.sayin@wlab.gu.se

Keywords: lung cancer, KRAS, chemotherapy, immunotherapy, biomarker

[1] Abbreviations

Word count: 3044
23

24
Abstract

***Purpose*:** There is an urgent need to identify new predictive biomarkers for treatment response

to both platinum doublet chemotherapy (PD) and immune checkpoint blockade (ICB) with

pembrolizumab. Here we evaluated whether treatment outcome could be affected by *KRAS*

mutational status in patients with metastatic (stage IV) non-small cell lung cancer (NSCLC).

***Methods*:** All consecutive patients molecularly assessed and diagnosed between 2016-2018

with stage IV NSCLC in the region of West Sweden were included in this multi-center

retrospective study. Primary study outcome was overall survival (OS).

***Results*:** Out of 580 stage IV NSCLC patients, 35.5% harbored an activating mutation in the

KRAS gene (KRAS^{MUT}). Compared to *KRAS* wild-type (KRAS^{WT}), KRAS^{MUT} was a negative

factor for OS (p = 0.014). On multivariate analysis, KRAS^{MUT} persisted as a negative factor for

OS (HR 1.288, 95% CI 1.091-1.521, p = 0.003). When treated with first-line platinum doublet (*n*

= 195), KRAS^{MUT} is a negative factor for survival (p = 0.018) with median OS 9 months vs

KRAS^{WT} 11 months. On multivariate analysis, KRAS^{MUT} persisted as a negative factor for OS

(HR 1.564, 95%CI 1.124-2.177, p = 0.008). KRAS^{MUT} patients with high PD-L1 expression (PD-

L1^{high}) had better OS than PD-L1^{high} KRAS^{WT} patients (p = 0.036). In response to first-line ICB,

KRAS^{MUT} patients had a significant (p = 0.006) better outcome than KRAS^{WT} with a median OS

23 vs 6 months. On multivariable Cox analysis, KRAS^{MUT} status was an independent prognostic

factor for better OS (HR 0.349, 95%CI 0.148-0.822, p = 0.016).

***Conclusions*:** *KRAS* mutations is a positive predictive factor for treatment with pembrolizumab

and a negative predictive factor for platinum doublet chemotherapy as well as general OS in

stage IV NSCLC.

Background

Non-small cell lung cancer (NSCLC) is the most commonly diagnosed cancer worldwide with

2.1 million new cases and 1.8 million deaths annually [1]. NSCLC can be treated effectively with

local management of the primary tumor in early stages but the 5-year survival for patients with

advanced metastatic (stage IV) NSCLC is below 10% [2, 3] NSCLC generally tends to have a

high overall mutational burden mainly due to exposure of exogenous mutagens like tobacco

smoke but also air pollution, causing high genomic instability and inter-patient heterogeneity [4].

The treatment options for stage IV NSCLC patients have become dependent on molecular

profiling because of the introduction of small molecular kinase inhibitors (SMKIs) targeting

activating mutations in EGFR, ALK, BRAF, RET and ROS1 oncogenes [5]. Unfortunately, the

majority of stage IV patients do not harbor a targetable driving mutation, for which platinum-

based chemotherapy doublets (PD) has been the only available treatment option until recently.

The introduction of immune checkpoint blockade (ICB) targeting programmed death ligand 1

(PD-L1) or programmed cell death 1 (PD-1) proteins led to impressive clinical results [6-8].

Consequently, all stage IV patients without any clinically actionable mutations are assessed for

ICB, single or in combination with chemotherapy, as a first-line treatment option [9-12]. PD-L1

expression is the only validated predictive marker for response to immunotherapy. Yet, its

accuracy as an individual prediction tool is not as good as initially assumed since on one hand

PD-L1 negative patients have been reported as ICB responders while on the other, many

patients with tumors expressing high levels of PD-L1 are being reported as non-responders to

ICB therapy [9, 13]. Along these lines, a meta-analysis of six randomized controlled trials with

ICB showed that PD-L1 expression levels was neither prognostic nor predictive for OS [14].

The most frequent oncogenic driver in NSCLC is the Kirsten rat sarcoma viral oncogene (*KRAS*)

present in up to 40% of all cases and the most common mutations are G12C, G12V and G12D

[15, 16]. *KRAS* mutations have been considered to negatively influence the prognosis of

NSCLC. Accordingly, *KRAS* mutations have been associated with a shorter OS following first

line PD treatment in more recent studies [17-21]. Attempts to target mutant KRAS and its

downstream mediators in cancer therapy remain largely unsuccessful [4, 22]. However, two

inhibitors efficiently targeting mutant KRAS-G12C have been developed but the clinical efficacy

is yet to be determined in ongoing trials [23-27]. Concurrently, it has been suggested that

NSCLC harboring *KRAS* mutations might benefit from ICB therapy compared to KRAS wild type

tumors [28]. Nevertheless, retrospective real-world data have so far shown inconclusive results

[28-33].

The gradual introduction of ICB treatment in recent years dawned a new era with high hopes for

patients with stage IV NSCLC. Clinical trials have shown ICB as being superior to chemotherapy

in patients harboring tumors with high tumor proportion score (TPS) ≥50% for PD-L1. These

results were confirmed in a recent network meta – analysis [7, 8, 10, 34]. However, the impact of

mutant KRAS was not addressed in these analyses. In addition, multiple real-world studies have

reported conflicting results regarding the impact of mutant KRAS on ICB response. In early days

of immunotherapy, only PD-L1 ≥ 50% patients were included in first-line ICB-treatment. We

know now that PD-L1 negative patients may also respond to ICB [9, 13]. Interestingly, some

studies suggest that PD-L1 expression per se might have a prognostic impact on NSCLC [35,

36].

By including all consecutive patients molecularly assessed and diagnosed with stage IV NSCLC

between 2016-2018 in west Sweden, the current retrospective cohort study provides a unique

real-world dataset for assessing the impact of *KRAS* mutations and PD-L1 expression on OS

following first-line standard of care, including platinum doublet chemotherapy and

immunotherapy with pembrolizumab.

Materials and Methods

Patient population

We conducted a multi-centers retrospective study including all consecutive NSCLC patients diagnosed with stage IV NSCLC and having molecular assessment performed between 2016-2018 in the Region Västra Götaland (region of West Sweden), Sweden ($n = 580$). Approval from the Swedish Ethical Review Authority (Dnr 2019-04771) was obtained prior to study commencement. All patients with available tissue sample where an adenocarcinoma component could not be excluded were systematically assessed with NGS for known genetic drivers (see below) within clinical praxis. Patient demographics (including age, gender, Eastern Cooperative Oncology Group (ECOG) performance status and smoking history), cancer stage, number of metastasis locations, pathological details (histology, mutation status including *KRAS* mutational status and subtype), treatment and outcome data were retrospectively collected from patient charts and the Swedish Lung Cancer Registry.

Mutational status

Patients were assessed with NGS for mutational status on DNA from FFPE blocks or cytological smears using the Ion AmpliSeq™ Colon and Lung Cancer Panel v2 from Thermo Fisher Scientific as a part of the diagnostic workup process at the Department of Clinical Pathology at Sahlgrenska University Hospital, assessing hotspot mutations in EGFR, BRAF, KRAS and NRAS. Until June 2017, ALK-fusions were assessed with immunohistochemistry (IHC), and with fluorescence in situ hybridization (FISH) if positive or inconclusive IHC; ROS1 was analyzed upon request with FISH. Thereafter, ALK, ROS1 and RET fusions were assessed on RNA using the Oncomine Solid Tumor Fusion Panel from Thermo Fisher Scientific.

PD-L1 expression

Programmed death ligand 1 (PD-L1) expression was determined based on percentage of tumor

cells with positive membranous staining and was reported as the tumor proportion score (TPS).

PD-L1 negative TPS <1%, low TPS 1%-49%, high TPS ≥50%. PD-L1 expression was detected

using the PD-L1 IHC 28-8 pharmDx system during routine diagnostic workup and staining was

assessed by lung pathologists.

ICB treatment

During the time period of this study, the only ICB treatment approved for first-line treatment was

Pembrolizumab, a humanized antibody targeting PD-1. The criteria was PD-L1^{high} TPS ≥50% for

first-line and PD-L1^{low} TPS ≥1% for second line treatment.

PD treatment

Platinum doublet treatment consists of carboplatin or cisplatin in combination with one more non-

platinum chemotherapy agent such as pemetrexed, vinorelbin, gemcitabine, paclitaxel,

etoposide or vincristine.

Study objectives

The primary outcome of this study was OS, defined as the interval between the date of

diagnostic sample collection and the date of death from any cause. Patients alive or lost to

follow-up at data were censored at last contact. Median follow up time was 7 months.

We compared OS stratified on KRAS^{WT} and KRAS^{MUT} for the entire cohort, for all patients

receiving life extending treatment excluding patients receiving best supportive care or palliative

radiotherapy (e.g., single tumor radiation for pain relief), and for all patients receiving PD or ICB

as first-line treatment. We also investigated the impact of TPS score (negative, low and high) on

OS, stratified on KRAS mutational status.

Statistical analysis

Clinical characteristics were summarized using descriptive statistics and evaluated with

univariate analysis. Kaplan Meier survival curves were generated to assess OS. Log-rank test

was used to assess significant differences in OS between groups. Multivariable Cox regression

analysis was conducted to compensate for potential confounders. Statistical significance was set

at $p<0.05$ and no adjustments were made for multiple comparisons. One-sided Fisher´s Exact

Test was used to determine the connection between KRAS status to being alive in the ICB-

treated group. Data analysis was conducted using IBM SPSS Statistics version 27 and

GraphPad Prism version 9.

Results

Patients and tumor characteristics

A total of 597 consecutive patients diagnosed with stage IV NSCLC were molecularly assessed

during 2016-2018 in West Sweden. A total of 17 patients were excluded for having incomplete

medical records, for receiving palliative treatment before 2016, for incorrect diagnosis or for

receiving simultaneous treatment for another type of cancer (Figure. 1A). Among the 580

included patients, more than a third harbored a *KRAS* mutation (206, 35.5%), the majority were

female (326, 56.2%), the median age was 71 years and 80 % were current or former smokers

(Table 1). The majority of patients (322, 55.5%) had a good Performance Status (PS) with low

ECOG 0-1 at diagnosis (Table 1). Histologically, the vast majority of NSCLCs were

adenocarcinoma of the lung (498, 85.9%) while squamous cell carcinoma cases were relatively

low which was expected due to the selection of histological type for NGS assessment (32, 5.5%)

(Table 1). In line with earlier studies, patients diagnosed with a low ECOG score had a

significantly better overall survival (OS), compared to patients diagnosed with a higher ECOG

score ($p = 0.0001$) (Supplemental Figure. 1A) [3, 37]. In addition, higher number of metastasis

locations at diagnosis correlated with poor OS ($p = 0.0002$) (Supplemental Figure. 1B), which

was expected [3, 37]. Furthermore, there was a trend towards better OS for females compared

to males (p = 0.064) (Supplemental Figure. 1C) [37, 38]. When comparing the baseline

characteristics of KRAS^{WT} with KRAS^{MUT} patients, there were more females and a higher

proportion of current and former smokers in the KRAS^{MUT} population (Table 1).

KRAS mutations is a negative factor for overall survival in stage IV NSCLC

Survival estimates for the whole study cohort displayed that _KRAS_ mutations was a significant

negative factor for overall survival (p = 0.014) (Figure. 1B). On multivariate Cox regression

analysis, KRAS^{MUT} status and male sex were independent prognostic factors for worse OS (HR

1.288, 95%CI 1.091-1.521, p = 0.003 and HR 1.179, 95%CI 1.009-1.378, p = 0.038). The

population that received any type of life extending treatment (n = 388), excluding patients only

receiving best supportive care or palliative radiotherapy (e.g., single tumor radiation for pain

relief) did not show a significant difference in OS between KRAS^{MUT} and KRAS^{WT} (p = 0.095)

(Figure. 1C).

When treated with first-line PD, one of standard treatments at the time, (n = 219), KRAS^{MUT} is a

significant negative factor for survival (p = 0.001) with median OS 9 months vs KRAS^{WT} 14

months (Figure. 2A). Baseline characteristics of the patients show that around 20% of KRAS^{WT}

patients displayed a druggable genomic alterations in ALK or EGFR (Supplemental Table 1). To

eliminate the risk of these patients driving any difference between KRAS^{MUT} and KRAS^{WT} groups

due to potentially receiving targeted therapies in the second line of treatment, we excluded all

patients with EGFR mutations and ALK fusions from the KRAS^{WT} group from further analysis.

Nevertheless, in patients receiving first-line PD chemotherapy (n = 195), KRAS^{MUT} is a

significant (p = 0.018) negative factor for survival (Figure. 2B), with median OS 9 months for

KRAS^{MUT} vs 11 months for KRAS^{WT}. In multivariate Cox regression analysis, KRAS^{MUT} status

and ECOG 2 or higher were independent prognostic factors for worse OS (HR 1.564, 95%CI

1.124-2.177, p = 0.008 and HR 1.906, 95%CI 1.307-7,779, p <0.001).

Overall survival for stage IV NSCLC treated with first-line PD or ICB stratifies based on *KRAS* mutational status

When comparing OS for all stage IV patients receiving PD (n =195) or ICB (n = 37) in a first-line setting, there was no difference between the two treatment groups (p = 0.678), median OS 11 months for PD vs 13 months for ICB (Figure. 3A). KRAS^{MUT} patients treated with ICB (n = 20) had a significantly (p = 0.003) better outcome compared to patients treated with PD (n = 104), median OS 23 vs 9 months (Figure. 3B). KRAS^{WT} patients treated with ICB (n = 17) had significantly (p = 0.023) worse survival than patients treated with PD (n = 91,) median OS 6 vs 11 months (Figure. 3C).

PD-L1 expression in tumors from stage IV patients is a positive factor for overall survival in KRAS^{MUT} but not KRAS^{WT} patients

Currently, tumoral PD-L1 expression is the only biomarker for ICB treatment widely used in the clinic for NSCLC [39, 40]. When analyzing all treated stage IV NSCLC patients with known PD-L1 status (n = 261) stratified on *KRAS* mutational status and PD-L1 expression levels (negative, low or high) (Figure. 4A), we observed that increased PD-L1 expression correlated with significant better OS in KRAS^{MUT} patients (p = 0.036, Figure 4B). KRAS^{MUT} patients clearly separate on OS between PD-L1 negative, low and high groups with median OS 6, 11 and 17 months respectively (Figure. 4B). No correlation between PD-L1 expression and OS in KRAS^{WT} patients was observed (Figure. 4C). There was a larger proportion of PD-L1^{high} in the KRAS^{MUT} population compared to KRAS^{WT} (43.0% vs 32.7%).

***KRAS* mutations are a positive factor for overall survival in patients with PD-L1^{high} tumors receiving immunotherapy.**

We next analyzed the specific impact of PD-L1^{high} expression on OS comparing all PD-treated vs ICB-treated patients: outcome was significantly improved for KRAS^{MUT} patients on ICB treatment (p = 0.028) with median OS being 9 vs 23 months (Figure 5A). KRAS^{WT} PD-L1^{high} patients

displayed a worse outcome for patients on ICB treatment compared to PD treatment (p = 0.010)

with median OS 6 months vs 28 months for each respective treatment (Figure. 5B). Importantly,

the KRAS[MUT] group had a significantly (p = 0.006) better outcome on ICB treatment compared to

the KRAS[WT] group with a median OS 23 vs 6 months (Figure. 5C, Supplemental Table 2). On

multivariate Cox regression analysis, KRAS[MUT] status and ECOG PS 0-1 were independent

prognostic factors for better OS following first-line ICB (HR 0.349, 95%CI 0.148-0.822, p = 0.016

and HR 0.398, 95%CI 0.165-0.963, p = 0.041). Finally, when looking at all patients treated with

pembrolizumab individually, there were significantly more KRAS[MUT] patients alive at last follow-

up compared to KRAS[WT] patients (50% vs 11.8%, p = 0.0152) (Figure 5D).

Discussion

The predictive value of *KRAS* mutations for survival in stage IV NSCLC patients is still not

clearly defined. While some studies have reported *KRAS* mutations to be a negative factor for

survival estimates [3, 22, 41], others have shown this not to be the case [42]. The current

retrospective cohort study shows a clear difference in OS for stage IV NSCLC patients when

stratified on *KRAS* mutational status. Previous studies have shown that *KRAS* mutations were

associated with a shorter OS in response to chemotherapy [18, 19]. In line with these studies,

our data show that KRAS[MUT] is a potential predictive negative factor for PD treatment. This is of

importance, especially in light of todays' new treatment options available such as

immunotherapy. Indeed, when stratifying stage IV NSCLC patients receiving first line

pembrolizumab monotherapy on *KRAS* mutational status, there is a clear increase in survival for

KRAS[MUT] patients.

Translational studies have suggested that KRAS[MUT] patients might respond well to ICB due to a

larger proportion of smokers and a higher immunologically active tumor environment as a

consequence of constitutive activation of KRAS and downstream signaling pathways [28-32, 37,

43, 44]. In agreement, our data shows that first-line pembrolizumab monotherapy led to a

clinically meaningful improvement in OS for KRAS^{MUT} patients when compared to first-line

platinum doublet treatment. Furthermore, PD-L1 status had a clear and significant impact on

stratifying OS in the KRAS^{MUT} group receiving treatment whereas no difference was observed for

the KRAS^{WT} group, which is in line with a previous study reporting a similar trend for KRAS^{MUT}

NSCLC receiving ICB treatment [33].

Interestingly, KRAS^{WT} patients showed a better response to PD treatment than

pembrolizumab monotherapy. This might be explained by KRAS^{WT} being a heterogeneous group

with the majority of patients not having an identified driving mutation, especially as patients with

targetable alterations in ALK and EGFR were excluded from further analysis.

There are several retrospective studies showing different outcomes when comparing

KRAS^{MUT} and KRAS^{WT} response to pembrolizumab. These discrepancies could be explained by

major study design differences such as inclusion of several different stages at diagnosis,

multiple treatment lines considered and inclusion of patients with no known PD-L1 status [28-33,

37]. A recent registry study from the Netherlands reported no difference in OS for PD-L1^{high}

patients receiving first-line pembrolizumab monotherapy but the fraction of patients where *KRAS*

mutations status had been assessed and reported to the registry was uncertain and could only

be approximated (at around 75%) [37]. However, a meta-analysis of randomized controlled trials

showed a significant OS benefit for KRAS^{MUT} patients in first-line immunotherapy with or without

chemotherapy vs. chemotherapy alone [44], which is in line with the current study. Among these,

the retrospective analysis of the phase 3 study KEYNOTE042 indicated a clear trend towards

better OS in the KRAS^{MUT} group when comparing first-line pembrolizumab versus platinum-

containing chemotherapy (28 vs 11 months) than for the patients with KRAS^{WT} (15 vs 12

months) [43], albeit only 301 out of 782 patients were molecularly assessed for KRAS status

among which 69 KRAS^{MUT} cases were identified. Importantly, KEYNOTE042 did not address the

impact of *KRAS* mutations on PD treatment outcome. In our cohort, 580 patients were assessed

and 206 KRAS^{MUT} patients were identified. To the best of our knowledge, our retrospective

cohort study is the largest to date comparing response to first-line ICB and PD therapy in stage

IV NSCLC patients where the *KRAS* mutational status is known for all patients.

Currently, pembrolizumab is a first-line immunotherapy option for all NSCLC patients with PD-

L1^{high} expression independently of *KRAS* mutational status. Our study suggests that additional

biomarkers for ICB response beyond PD-L1^{high} is clearly warranted, in line with other studies [9,

13, 14]. Indeed, KRAS^{WT} patients with PD-L1^{high} tumoral expression responded better to PD

chemotherapy than to pembrolizumab. In contrast, KRAS^{MUT} patients clearly benefited more

from pembrolizumab treatment (50% alive at last follow-up). Our results suggest that tumoral

PD-L1^{high} expression in combination with *KRAS* mutations is a better predictive biomarker for

ICB with pembrolizumab in stage IV NSCLC than PD-L1^{high} expression alone.

Limitations

Although this study provides real-world evidence of the impact of *KRAS* mutational status on

first-line therapy in a large and well controlled group of stage IV NSCLC patients, it is obviously

limited by its retrospective nature. Despite the fact that all stage IV NSCLC patients molecularly

assessed in the region of West Sweden 2016-2018 were included in this cohort study, a

relatively small number of patients were treated with first-line ICB therapy when compared to

first-line PD therapy. Hence pooled analyses from multi-cohort studies will be important to

validate and expand our findings.

Conclusion

Here we report that *KRAS* mutations are a positive predictive factor for immunotherapy with

pembrolizumab and a negative predictive factor for platinum doublet chemotherapy as well as

general OS in stage IV NSCLC. Our findings suggest that *KRAS* mutations combined with PD-

L1^{high} expression is a better predictive biomarker than only PD-L1^{high} for response to first-line

immunotherapy with pembrolizumab in patients with stage IV NSCLC.

Acknowledgements

We thank Sayin lab members for critical reading of the manuscript. In addition, we thank

members of the of the Swedish Lung Cancer Registry, and the continuous reporting by Swedish

healthcare employees.

Funding

This work was supported by the Swedish Society for Medical Research (2018; S18-034), the

Swedish Cancer Society, the Medical Research Council (2018; 2018-02318), AG Fond (2020),

the Knut and Alice Wallenberg Foundation and the Wallenberg Centre for Molecular and

Translational Medicine (to V.I.S.); the Gothenburg Society of Medicine (2019; 19/889991) and

Department of Oncology, Sahlgrenska University Hospital (to E.A.E.); the Swedish Cancer

Society and The Healthcare Board for the Region of West Sweden (to S.R); Sahlgrenska

Academy, Gothenburg University (2019; GU2019-3467) (to C.W.); the Swedish government

under the LUA/ALF agreement (to H.F.); the Swedish Cancer Society (2017; 17-0171) and the

Swedish government under the LUA/ALF agreement (ALFGBG-495961) (to L.M.A.)

Declaration of potential conflict of interest

The authors have declared no conflicts of interest.

References

1. *World Health Organization, International Agency for Research on Cancer. Globocan 2020: Lung Cancer. International Agency for Research on Cancer. Available at* http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. *Accessed: March 2, 2021.*

2. *Swedish Lung cancer registry- Avaliable from:* https://cancercentrum.se/samverkan/cancerdiagnoser/lunga-och-lungsack/vardprogram/. .

3. El Osta, B., et al., *Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.* J Thorac Oncol, 2019. **14**(5): p. 876-889.

4. Herbst, R.S., D. Morgensztern, and C. Boshoff, *The biology and management of non-small cell lung cancer.* Nature, 2018. **553**(7689): p. 446-454.

5. König, D., S. Savic Prince, and S.I. Rothschild, *Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.* Cancers (Basel), 2021. **13**(4).

6. Herbst, R.S., et al., *Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.* N Engl J Med, 2020. **383**(14): p. 1328-1339.

7. Reck, M., et al., *Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.* J Clin Oncol, 2021. **39**(21): p. 2339-2349.

8. Reck, M., et al., *Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.* J Clin Oncol, 2019. **37**(7): p. 537-546.

9. Borghaei, H., et al., *Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.* Cancer, 2020. **126**(22): p. 4867-4877.

10. Ferrara, R., et al., *Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.* Cochrane Database Syst Rev, 2021. **4**(4): p. Cd013257.

11. Frederickson, A.M., et al., *Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis.* Immunotherapy, 2019. **11**(5): p. 407-428.

12. Gandhi, L., et al., *Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.* N Engl J Med, 2018. **378**(22): p. 2078-2092.

13. Rittmeyer, A., et al., *Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.* Lancet, 2017. **389**(10066): p. 255-265.

14. Zhang, B., et al., *Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.* Int Immunopharmacol, 2020. **80**: p. 106214.

15.   Adderley, H., F.H. Blackhall, and C.R. Lindsay, *KRAS-mutant non-small cell lung cancer:*
Converging small molecules and immune checkpoint inhibition. EBioMedicine, 2019. **41**:
p. 711-716.
16.   Ferrer, I., et al., *KRAS-Mutant non-small cell lung cancer: From biology to therapy.* Lung
Cancer, 2018. **124**: p. 53-64.
17.   Brady, A.K., et al., *Survival outcome according to KRAS mutation status in newly*
diagnosed patients with stage IV non-small cell lung cancer treated with platinum
doublet chemotherapy. Oncotarget, 2015. **6**(30): p. 30287-94.
18.   Hames, M.L., et al., *Correlation between KRAS mutation status and response to*
chemotherapy in patients with advanced non-small cell lung cancer. Lung Cancer, 2016.
92: p. 29-34.
19.   Marabese, M., et al., *KRAS mutations affect prognosis of non-small-cell lung cancer*
patients treated with first-line platinum containing chemotherapy. Oncotarget, 2015.
6(32): p. 34014-22.
20.   Mellema, W.W., et al., *KRAS mutations in advanced nonsquamous non-small-cell lung*
cancer patients treated with first-line platinum-based chemotherapy have no predictive
value. J Thorac Oncol, 2013. **8**(9): p. 1190-5.
21.   Rodenhuis, S., et al., *Mutational activation of the K-ras oncogene and the effect of*
chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin
Oncol, 1997. **15**(1): p. 285-91.
22.   Meng, D., et al., *Prognostic value of K-RAS mutations in patients with non-small cell lung*
cancer: a systematic review with meta-analysis. Lung Cancer, 2013. **81**(1): p. 1-10.
23.   Addeo, A., G.L. Banna, and A. Friedlaender, *KRAS G12C Mutations in NSCLC: From Target*
to Resistance. Cancers (Basel), 2021. **13**(11).
24.   Burns, T.F., et al., *Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at*
a Time, With a Focus on KRAS G12C Mutations. J Clin Oncol, 2020. **38**(35): p. 4208-4218.
25.   Indini, A., et al., *Targeting KRAS in Solid Tumors: Current Challenges and Future*
Opportunities of Novel KRAS Inhibitors. Pharmaceutics, 2021. **13**(5).
26.   Mathieu, M., et al., *KRAS G12C fragment screening renders new binding pockets.* Small
GTPases, 2021: p. 1-14.
27.   Skoulidis, F., et al., *Sotorasib for Lung Cancers with KRAS p.G12C Mutation.* N Engl J Med,
2021.
28.   Liu, C., et al., *The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant*
non-small cell lung cancer that correlates with an inflammatory phenotype and increased
immunogenicity. Cancer Lett, 2020. **470**: p. 95-105.
29.   Cinausero, M., et al., *KRAS and ERBB-family genetic alterations affect response to PD-1*
inhibitors in metastatic nonsquamous NSCLC. Ther Adv Med Oncol, 2019. **11**: p.
1758835919885540.
30.   Gianoncelli, L., et al., *Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small*
Cell Lung Cancer Patients: A Retrospective Analysis. Anticancer Res, 2020. **40**(1): p. 427-
433.
31.   Karatrasoglou, E.A., et al., *Association between PD-L1 expression and driver gene*
mutations in non-small cell lung cancer patients: correlation with clinical data. Virchows
Arch, 2020. **477**(2): p. 207-217.

32.   Torralvo, J., et al., *The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-*
409   *small Cell Lung Cancer: A Single Centre Experience.* Cancer Genomics Proteomics, 2019.
410   **16**(6): p. 577-582.
411   33.   Jeanson, A., et al., *Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small*
412   *Cell Lung Cancer (NSCLC).* J Thorac Oncol, 2019. **14**(6): p. 1095-1101.
413   34.   Herbst, R., et al., *A Network Meta-Analysis of Cancer Immunotherapies Versus*
414   *Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and*
415   *High Programmed Death-Ligand 1 Expression.* Front Oncol, 2021. **11**: p. 676732.
416   35.   Arak, H., et al., *Prognostic and Predictive Significance of PD-L1 Expression in Non-Small*
417   *Cell Lung Cancer Patients: A Single-Center Experience.* Turk Patoloji Derg, 2021. **37**(3): p.
418   239-248.
419   36.   Wang, A., et al., *The prognostic value of PD-L1 expression for non-small cell lung cancer*
420   *patients: a meta-analysis.* Eur J Surg Oncol, 2015. **41**(4): p. 450-6.
421   37.   Noordhof, A.L., et al., *Prognostic impact of KRAS mutation status for patients with stage*
422   *IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy.* Lung
423   Cancer, 2021. **155**: p. 163-169.
424   38.   Dogan, S., et al., *Molecular Epidemiology of EGFR and KRAS*
425   *Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-*
426   *Related KRAS-Mutant Cancers.* 2012. **18**(22): p. 6169-6177.
427   39.   Darabi, S., et al., *Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-*
428   *L1.* Oncology (Williston Park), 2020. **34**(8): p. 321-327.
429   40.   Niu, M., et al., *Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC.* Exp Hematol
430   Oncol, 2021. **10**(1): p. 18.
431   41.   Hallqvist, A., et al., *Mutated KRAS Is an Independent Negative Prognostic Factor for*
432   *Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy.* Lung Cancer
433   Int, 2012. **2012**: p. 587424.
434   42.   Sebastian, M., et al., *KRAS G12C-mutated advanced non-small cell lung cancer: A real-*
435   *world cohort from the German prospective, observational, nation-wide CRISP Registry*
436   *(AIO-TRK-0315).* Lung Cancer, 2021. **154**: p. 51-61.
437   43.   Herbst, R.S., et al., *LBA4 Association of KRAS mutational status with response to*
438   *pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-*
439   *squamous NSCLC in Keynote-042.* Annals of Oncology, 2019. **30**: p. xi63-xi64.
440   44.   Landre, T., et al., *Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a*
441   *meta-analysis of randomized-controlled trials.* Cancer Immunol Immunother, 2021.
442
443
444

Figure legends

Table 1 Characteristics of the total cohort as well as stratified on KRAS^{WT} and KRAS^{MUT}. Data are presented as n (%).

ECOG PS, Eastern Cooperative Oncology Group Performance Status.

Figure 1. *KRAS* mutations is a negative factor for overall survival

A. Flow chart showing the patient selection for the study.

B. Kaplan-Meier estimates comparing overall survival and median survival stratified on KRAS^{WT} vs KRAS^{MUT} for the full cohort ($n = 580$). Pie chart showing patient distribution between KRAS^{WT} and KRAS^{MUT}.

C. Kaplan-Meier estimates comparing overall survival for all receiving life extending treatment (no treatment and only palliative radiotherapy excluded) stratified on KRAS^{WT} vs KRAS^{MUT}. Pie chart showing patient distribution between KRAS^{WT} and KRAS^{MUT}.

Figure 2. KRAS^{MUT} is a negative factor for overall survival when treated with platinum doublet independently of EGFR and ALK mutations.

A. Kaplan-Meier estimates comparing overall survival for all receiving treatment with platinum doublet stratified on KRAS^{WT} vs KRAS^{MUT}. Pie chart showing patient distribution between KRAS^{WT} and KRAS^{MUT}.

B. Kaplan-Meier estimates comparing overall survival for all receiving treatment with platinum doublet stratified on KRAS^{WT} vs KRAS^{MUT}. Patients with EGFR and ALK alterations are excluded from KRAS^{WT} group. Pie chart showing patient distribution between KRAS^{WT} and KRAS^{MUT}.

Figure 3. KRAS^{MUT}, but not KRAS^{WT}, has a better outcome on ICB than platinum doublet treatment.

A. Kaplan-Meier estimates comparing overall survival for all patients, excluding patients with

ALK or EGFR alterations, receiving treatment with PD vs ICB. Pie chart showing patient

distribution between PD and ICB.

B. Kaplan-Meier estimates comparing overall survival for all KRAS^{MUT} receiving treatment with

PD vs ICB. Pie chart showing patient distribution between platinum doublet and ICB.

C. Kaplan-Meier estimates comparing overall survival for KRAS^{WT}, excluding patients with ALK

or EGFR alterations, receiving treatment with platinum doublet vs ICB. Pie chart showing patient

distribution between PD and ICB.

ICB: Immune Checkpoint Blockade; PD: Platinum Doublet

Figure 4. PD-L1 status has an impact on overall survival for treated patients with KRAS^{MUT}

A. IHC depicting examples of PD-L1 staining used to assess PD-L1 status in both KRAS^{WT} and

KRAS^{MUT} NSCLC patients. PD-L1 expression is classified as negative, < 50% or ≥50% based on

tumor proportion score.

B. Kaplan-Meier estimates comparing overall survival for KRAS^{MUT} treated patients stratified on

PD-L1 status. Pie chart showing patient distribution between PD-L1 negative, <50% and ≥50%.

C. Kaplan-Meier estimates comparing overall survival for KRAS^{WT} treated patients stratified on

PD-L1 status. Pie chart showing patient distribution between PD-L1 negative, <50% and ≥50%.

IHC: Immunohistochemistry; PD-L1: Programmed Death Ligand 1

Figure 5. KRAS^{MUT} patients have a better outcome on ICB treatment than KRAS^{WT} patients

A. Kaplan-Meier estimates comparing overall survival for KRAS^{MUT} PD-L1 ≥50% treated patients

receiving PD or ICB. Pie chart showing patient distribution receiving PD or ICB treatment.

B. Kaplan-Meier estimates comparing overall survival for KRAS^{WT} PD-L1≥50% treated patients

receiving PD or ICB. Pie chart showing patient distribution receiving PD or ICB treatment.

C. Kaplan-Meier estimates comparing overall survival for all patients receiving ICB treatment in a

first-line setting. Pie chart showing patient distribution between KRAS^{WT} and KRAS^{MUT}.

D. Waterfall plot showing survival time (difference from median survival) for both KRAS^{WT} and

KRAS^{MUT} pembrolizumab-treated patients. Status alive at last follow-up is shown.

ICB: Immune Checkpoint Blockade; PD: Platinum Doublet; PD-L1: Programmed Death Ligand 1

Supplemental Figure 1

A. Kaplan-Meier estimates comparing overall survival for the full cohort stratified on ECOG PS.

Pie chart showing patient distribution between ECOG stages.

B. Kaplan-Meier estimates comparing overall survival for the full cohort stratified on number of

metastasis locations. Pie chart showing patient distribution between number of metastasis

locations.

C. Kaplan-Meier estimates comparing overall survival for the full cohort stratified on gender. Pie

chart showing patient distribution between male and female.

ECOG: Eastern Cooperative Oncology Group; PS: Performance Status

Supplemental Table 1 (Related to Figure. 2A)

Characteristics of all PD treated patients.

Supplemental Table 2 (Related to Figure 5A)

Characteristics of all patients treated with first-line ICB

Eklund et al. Figure 1

A

B

C

Eklund et al. Figure 2

A

PLATINUM DOUBLET treated patients

median survival   *n* = 219

KRAS^WT (14 months)
KRAS^MUT (9 months)

p = 0.001

B

PLATINUM DOUBLET treated patients
Alterations in EGFR and ALK excluded

median survival   *n* = 195

KRAS^WT (11 months)
KRAS^MUT (9 months)

p = 0.018

Eklund et al. Figure 3

A

PD and Pembrolizumab treated patients

B

PD and Pembrolizumab treated KRAS^MUT patients

C

PD and Pembrolizumab treated KRAS^WT patients

Eklund et al. Figure 4

A

B

C

Eklund et al. Figure 5